The Effects of Recombinant Human Erythropoietin on Perioperative Transfusion Requirements in Patients Having a Major Orthopaedic Operation*
- 1 January 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 78 (1), 62-72
- https://doi.org/10.2106/00004623-199601000-00009
Abstract
Two hundred patients who were scheduled for a major elective orthopaedic operation were enrolled in a prospective study and were randomly assigned to one of three treatment groups. Group 1 consisted of sixty patients who received recombinant human erythropoietin, 300 international units perThis publication has 19 references indexed in Scilit:
- Effectiveness of perioperative recombinant human erythropoietin in elective hip replacementThe Lancet, 1993
- The International Standard for Recombinant DNA-derived Erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietinsJournal of Endocrinology, 1992
- Recombinant human erythropoietin treatment improves platelet function in uremic patientsKidney International, 1992
- A comparison of the responses to recombinant human erythropoietin in normal and uremic subjectsKidney International, 1992
- Statistics in the Journal of Bone and Joint SurgeryJournal of Bone and Joint Surgery, 1992
- Pancreaticoduodenectomy Without Homologous Blood Transfusion in an Anemic Jehovah's WitnessArchives of Surgery, 1992
- Use of human rocombinant erythropoietin to correct severe preoperative anemiaThe Annals of Thoracic Surgery, 1991
- Preoperative erythropoietin in Jehovah's Witnesses who require cardiac proceduresThe Annals of Thoracic Surgery, 1991
- Preoperative Use of Erythropoietin in an Adolescent Jehovah's WitnessAnesthesiology, 1990
- Increased Preoperative Collection of Autologous Blood with Recombinant Human Erythropoietin TherapyNew England Journal of Medicine, 1989